September 3, 2026
Novartis signs deal with Alteogen for drug delivery
Novartis has signed an agreement with Alteogen that could be worth up to $3.22bn for the development and commercialisation of subcutaneous drug formulations using Alteogen’s ALT-B4 technology.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







